US2016185789A1PendingUtilityA1

Process for preparing oxycodone compositions

67
Assignee: PURDUE PHARMA LPPriority: Mar 30, 2004Filed: Mar 4, 2016Published: Jun 30, 2016
Est. expiryMar 30, 2024(expired)· nominal 20-yr term from priority
Inventors:Robert ChapmanLonn S. RiderQi-Zhong HongDonald J. KyleRobert Kupper
A61P 29/00A61P 25/04A61K 9/14A61K 31/485C07D 489/08C07D 489/02A61K 9/20A61K 9/0053A61K 47/30A61K 9/2095A61K 9/48C07D 489/04A61K 9/4833
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.

Claims

exact text as granted — not AI-modified
1 - 79 . (canceled) 
     
     
         80 . A process for preparing an oxycodone salt composition that is substantially free of 14-hydroxycodeinone comprising:
 contacting an oxycodone base composition having an amount of 8α,14-dihydroxy-7,8-dihydrocodeinone with a substance that preferentially removes 8α,14-dihydroxy-7,8-dihydrocodeinone as compared to the oxycodone base; and   converting the oxycodone base composition to the oxycodone salt composition that is substantially free of 14-hydroxycodeinone.   
     
     
         81 . The process of  claim 80 , wherein the oxycodone salt composition comprises less than 100 ppm 14-hydroxycodeinone. 
     
     
         82 . The process of  claim 81 , wherein the oxycodone salt composition comprises less than 25 ppm 14-hydroxycodeinone. 
     
     
         83 . The process of  claim 82 , wherein the oxycodone salt composition comprises less than 15 ppm 14-hydroxycodeinone. 
     
     
         84 . The process of  claim 83 , wherein the oxycodone salt composition comprises less than 10 ppm 14-hydroxycodeinone. 
     
     
         85 . The process of  claim 84 , wherein the oxycodone salt composition comprises less than 5 ppm 14-hydroxycodeinone. 
     
     
         86 . The process of  claim 81 , wherein the oxycodone salt composition comprises 0.5 ppm or more 14-hydroxycodeinone. 
     
     
         87 . The process of  claim 80 , wherein the process is for preparing an oxycodone hydrochloride active pharmaceutical ingredient composition. 
     
     
         88 . The process of  claim 80 , wherein the process is for preparing an oxycodone hydrochloride active pharmaceutical ingredient composition comprising less than 25 ppm 14-hydroxycodeinone. 
     
     
         89 . The process of  claim 80 , wherein the substance that preferentially removes the 8α,14-dihydroxy-7,8-dihydrocodeinone is a gel. 
     
     
         90 . The process of  claim 89 , further comprising forming a slurry with the oxycodone base composition and the gel. 
     
     
         91 . The process according to  claim 80 , wherein the oxycodone base composition is passed through the substance that preferentially removes the 8α,14-dihydroxy-7,8-dihydrocodeinone. 
     
     
         92 . The process of  claim 80 , further comprising controlling an acid catalyzed dehydration consisting of conversion of the 8α,14-dihydroxy-7,8-dihydrocodeinone to 14-hydroxycodeinone during the conversion of the oxycodone base composition to the oxycodone salt composition. 
     
     
         93 . The process of  claim 92 , further comprising reducing the rate of dehydration of the 8α,14-dihydroxy-7,8-dihydrocodeinone to 14-hydroxycodeinone during the conversion of the oxycodone base composition to the oxycodone salt composition. 
     
     
         94 . The process of  claim 93 , wherein at least some of the 8α,14-dihydroxy-7,8-dihydrocodeinone is dehydrated to 14-hydroxycodeinone during the conversion of the oxycodone base composition to the oxycodone salt composition. 
     
     
         95 . A process for preparing an oxycodone salt composition comprising less than 100 ppm 14-hydroxycodeinone comprising:
 contacting an oxycodone base composition having an amount of 8α,14-dihydroxy-7,8-dihydrocodeinone with a substance that preferentially removes 8α,14-dihydroxy-7,8-dihydrocodeinone as compared to the oxycodone base;   converting the oxycodone base composition to an oxycodone salt composition comprising less than 14-hydroxycodeinone; and   isolating the oxycodone salt composition comprising less than 100 ppm 14-hydroxycodeinone.   
     
     
         96 . The process of  claim 95 , further comprising controlling an acid catalyzed dehydration consisting of conversion of the 8α,14-dihydroxy-7,8-dihydrocodeinone to 14-hydroxycodeinone during the conversion of the oxycodone base composition to the oxycodone salt composition. 
     
     
         97 . The process of  claim 96 , further comprising reducing the rate of dehydration of the 8α,14-dihydroxy-7,8-dihydrocodeinone to 14-hydroxycodeinone during the conversion of the oxycodone base composition to the oxycodone salt composition. 
     
     
         98 . The process of  claim 97 , wherein at least some of the 8α,14-dihydroxy-7,8-dihydrocodeinone is dehydrated to 14-hydroxycodeinone during the conversion of the oxycodone base composition to the oxycodone salt composition. 
     
     
         99 . The process of  claim 95 , wherein the oxycodone salt composition comprises less than 25 ppm 14-hydroxycodeinone. 
     
     
         100 . The process of  claim 99 , wherein the oxycodone salt composition comprises less than 10 ppm 14-hydroxycodeinone. 
     
     
         101 . The process of  claim 100 , wherein the oxycodone salt composition comprises less than 5 ppm 14-hydroxycodeinone. 
     
     
         102 . The process of  claim 95 , wherein the oxycodone salt composition comprises 0.5 ppm or more 14-hydroxycodeinone. 
     
     
         103 . The process of  claim 102 , wherein the oxycodone salt composition comprises 1 ppm or more 14-hydroxycodeinone. 
     
     
         104 . The process of  claim 95 , wherein the process is for preparing an oxycodone hydrochloride composition. 
     
     
         105 . The process of  claim 95 , wherein the process is for preparing an oxycodone hydrochloride active pharmaceutical ingredient composition. 
     
     
         106 . The process of  claim 95 , wherein the process is for preparing an oxycodone hydrochloride active pharmaceutical ingredient composition comprising less than 25 ppm 14-hydroxycodeinone. 
     
     
         107 . The process of  claim 95 , wherein the isolated oxycodone salt composition comprises greater than 100 ppm 14-hydroxycodeinone. 
     
     
         108 . The process of  claim 107 , further comprising hydrogenating the oxycodone salt composition comprising greater than 100 ppm 14-hydroxycodeinone to decrease the level of 14-hydroxycodeinone. 
     
     
         109 . The process of  claim 108 , wherein the level of 14-hydroxycodeinone is decreased to less than 25 ppm.

Join the waitlist — get patent alerts

Track US2016185789A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.